FDA OKs Upfront Nivolumab+Chemo for Classic Hodgkin Lymphoma

Published Date: 23 Mar 2026

The agency also granted traditional approval to later-line nivolumab indications for certain adults with the disease.

Read Full News

Latest News

Older Adults With Advanced Cancer Prioritize Quality of Life

Most older adults with advanced cancer value quality of life over extending survival, but that preference may not translate to clinical care or outcomes.

MRI-Guided TULSA Speeds Recovery vs Robotic Prostatectomy

The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.

New Nanoparticles Can Destroy Undruggable Cancer Proteins

Researchers have created nanoparticles that can remove disease-driving proteins while also delivering a chemotherapeutic or immunotherapeutic payload to cancer cells.

Shorter but More Intense RT: A Better Option for HNSCC?

A new analysis explores whether accelerating RT delivery with 6 fractions vs 5 fractions per week improves outcomes in patients with locally advanced HNSCC receiving concurrent chemotherapy.

Adjuvant Tx May Boost Survival in Bilateral Breast Cancer

A population-based cohort study finds that an increased use of adjuvant systemic therapy can improve survival in patients with metachronous and synchronous bilateral breast cancer.

Chemoimmunotherapy Boosts Head and Neck Cancer Response

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

Todays Updates

Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer

In a new trial, patients with PD-L1 CPS ≥ 1 HNSCC were randomly assigned 1:1 to receive 20 mg/d lenvatinib orally plus pembrolizumab 200 mg intravenously or placebo orally once daily plus pembrolizumab 200 mg intravenously.

Todays Updates

Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer

In a new trial, patients with PD-L1 CPS ≥ 1 HNSCC were randomly assigned 1:1 to receive 20 mg/d lenvatinib orally plus pembrolizumab 200 mg intravenously or placebo orally once daily plus pembrolizumab 200 mg intravenously.

Latest News

Most older adults with advanced cancer value quality of life over extending survival, but that preference may not translate to clinical care or outcomes.

The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.

Researchers have created nanoparticles that can remove disease-driving proteins while also delivering a chemotherapeutic or immunotherapeutic payload to cancer cells.

A new analysis explores whether accelerating RT delivery with 6 fractions vs 5 fractions per week improves outcomes in patients with locally advanced HNSCC receiving concurrent chemotherapy.

A population-based cohort study finds that an increased use of adjuvant systemic therapy can improve survival in patients with metachronous and synchronous bilateral breast cancer.

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

News All Time

SBRT May Beat Brachytherapy in Prostate Cancer

In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.

When in Breast Cancer Treatment Are CDK4/6 Inhibitors Best?

Researchers examined whether CDK4/6 inhibitors lead to better overall survival when used as first- or second-line treatment.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

Patients with breast cancer living in states with expanded Medicaid eligibility, have seen survival gains, raising more concerns about the impact of recent changes to the program.

Cancer and HIV Vaccines Enter the Therapeutic Era

Therapeutic vaccines are advancing in oncology and HIV, with the aim of retraining immune responses to target tumors and persistent viral reservoirs with precision.

FDA Approves Monthly Dosing of Rybrevant Faspro for NSCLC

The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.

Home Screening Appeals to Women Facing Healthcare Barriers

Researchers asked more than 2000 women if they preferred at-home vaginal self-sampling over clinic-based testing to screen for cervical cancer.

Which Salvage Therapy Is Best for Recurrent Prostate Cancer?

Ten-year survival data support salvage focal therapy as an option for patients with localized recurrence after prostate cancer radiotherapy.

PSMA PET: Prostate Cancer Staging Revolution Awaits RCT Data

‘Step by step, little by little, we are learning how to act on this new staging information,’ one investigator says.

Stereotactic Radiation Linked to Better Brain Mets Outcomes

Researchers compared outcomes of stereotactic radiation and hippocampal-avoidance whole brain radiation in patients with 5-20 brain metastases.

Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL

The all-oral, fixed-duration treatment combination provided better PFS and safety than investigator’s choice of chemoimmunotherapy in the phase 3 AMPLIFY study.

Sudan Clinics Could Run Out of Supplies Due to Middle East War

Medical supplies to clinics dealing with the humanitarian crisis in Sudan could run out within 2 weeks unless ⁠shipments are rapidly rerouted.

Around 4.9 Million Children Under Five Died in 2024, Says UN

About 4.9 million children died before reaching their fifth birthday in 2024, according to new United Nations estimates, a sign progress ⁠to reduce child mortality rates was...

UK Races to Contain Meningitis Outbreak in Kent After Two Deaths

Britain will roll out meningitis vaccines to students at a university in southeast England after an "unprecedented" outbreak of the disease killed two people while the...

Pope Leo Calls Universal Healthcare a 'Moral Imperative'

Pope Leo has made a plea for countries ⁠to offer their citizens universal healthcare, calling it a "moral imperative" that people have access to ⁠the health services they need.

Will the UK Lose Senior Doctors Earlier Than EU Peers?

Findings from a Medscape survey suggest German and French doctors plan to work longer than their British counterparts — and it’s not just a lifestyle choice.